Randomized trials of PCIs versus CABG surgery: why coronary stenting should remain the first choice of revascularization in non-diabetic patients and why the controversy is still present in diabetics

Knowing the best revascularization option for diabetic patients with multiple vessel disease is a challenge without a definitive answer. There have been several randomized clinical trials and subsequent meta-analyses comparing current available technology trying to reach an exhaustive conclusion; comparisons between coronary artery bypass grafts and bare-metal stents, coronary artery bypass grafts and first generation drug-eluting stents and, most recently, first generation versus latest generation drug-eluting stents generated some interesting results. Information provided by pooled data from some of the most important randomized clinical cardiology trials from the last two decades have produced surprising results. The authors analyze these data to discuss the best therapeutic procedures for each patient.     

Current status of the Xience V® everolimus-eluting coronary stent system

The introduction of drug-eluting stents has led to a marked reduction of restenosis, which is a major limitation of percutaneous coronary intervention for coronary artery disease. The next-generation Xience V^® (Abbott Vascular, CA, USA) everolimus-eluting stent was designed to address the limitations of first-generation drug-eluting stents. The cobalt–chromium stent platform with an open-cell design offers excellent deliverability. Moreover, the combination of a thin fluoropolymer eluting the antirestenotic drug everolimus provides both an effective suppression of neointimal tissue and rapid re-endothelialization above and between stent struts in preclinical studies. Large randomized clinical trials comparing the everolimus-eluting stent with the Taxus Express^® and Liberté^® (Boston Scientific, MA, USA) paclitaxel-eluting stents have shown reduced rates of repeat revascularization, myocardial infarction and stent thrombosis at 1-year follow-up with the everolimus-eluting stent. However, we will have to await long-term (5-year) data from these randomized clinical trials with the everolimus-eluting stent to determine whether the observed benefit is robust. Furthermore, data are currently limited the clinical performance of the everolimus-eluting stent relative to drug-eluting stents other than the Taxus Express and Liberté paclitaxel-eluting stents, although a large number of trials are now being conducted to address these questions. In this article, we provide a comprehensive overview of (pre)clinical studies with the everolimus-eluting stent.     

单中心颈动脉狭窄患者支架植入术的远期疗效

目的探讨颈动脉狭窄患者行支架植入术的安全性及近、远期疗效。方法回顾性分析2005年1月至2010年12月在沈阳军区总医院住院的48例颈动脉狭窄患者,在远端脑保护装置下植入颈动脉支架,观察其围术期并发症及临床疗效。结果48例颈动脉狭窄患者,年龄（66±6.8）岁,男41例（85.4%,41/48）,靶病变1处/例,病变长度（22.5±10.3）mm,狭窄程度88.5%±9.9%。手术成功率100%,植入颈动脉自膨式支架1枚/例,使用远端滤网保护装置1个/例,支架直径（7.3±2.4）mm,长度（36.0±5.5）mm,术后即刻残余狭窄程度5.6%±4.5%。术中11例（22.9%,11/48）出现心率减慢,于术中给予1 mg阿托品静脉注射,心率恢复至正常范围。2例（4.2%,2/48）出现一侧肢体活动障碍,经治疗24 h后好转,术后无严重并发症发生。随访（36.2±15.5）个月,随访率93.8%（45/48）,2例（4.4%,2/48）患者死亡,其中1例死于肺癌,1例死于缺血性脑卒中,4例（8.9%,4/48）患者仍有头晕发作,3例（6.7%,3/48）偶有肢体麻木,无严重脑缺血发作,无脑梗死、脑出血发生。术后6～12个月复查增强计算机断层扫描：无颈动脉、椎动脉及肾动脉支架内再狭窄。结论在远端脑保护装置下行颈动脉支架植入术是治疗颈动脉狭窄安全有效的手段,手术成功率高,长期临床随访患者仍能从中获益。     

Advances in Endoscopic Ultrasound-Guided Biliary Drainage: A Comprehensive Review

Endoscopic retrograde cholangiopancreatography (ERCP) has become the first-line therapy for bile duct drainage. In the hands of experienced endoscopists, conventional ERCP results in a failed cannulation rate of 3% to 5%. This failure can occur more commonly in the setting of altered anatomy or technically difficult cases due to either duodenal or biliary obstruction. In cases of ERCP failure, patients have traditionally been referred for either percutaneous transhepatic biliary drainage (PTBD) or surgery. However, both PTBD and surgery have higher than desirable complication rates. Within the last decade, endoscopic ultrasound-guided biliary drainage (EUS-BD) has become an attractive alternative to PTBD after failed ERCP. Many groups have reported on the feasibility, efficacy and safety of this technique. This article reviews the indications for ERCP and the currently practiced EUS-BD techniques, including EUS-guided rendezvous, EUS-guided choledochoduodenostomy and EUS-guided hepaticogastrostomy.     

冠心病患者冠脉支架置入前后血清内脏脂肪素的变化及意义

 目的研究冠脉支架植入对冠心病患者血清内脏脂肪素表达的影响。方法将50例冠心病患者随机分为冠脉支架植入组和未接受支架植入的冠状血管造影组,于术前1d、术后1d、术后10d、术后30d取静脉血,检测患者血清脂肪素水平的变化。结果冠脉造影组手术前后各时间段血清脂肪素浓度的差异无统计学意义（P>0.05）;冠状血管造影组术后1d、术后10d、术后30d脂肪素的浓度持续升高,各时间段血清脂肪素浓度的差别有统计学意义（P<0.01）。结论单纯冠脉造影不影响冠心病患者脂肪素表达,冠脉支架植入后一个月内脂肪素持续升高,分析脂肪素可能与内皮损伤修复有关。